Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

DiaMedica Therapeutics, Inc. DMAC

Healthcare  —  Biotechnology
7.94 0.11 1.40% as of 25 Sep
Market cap
$422.2M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

DiaMedica Therapeutics, Inc. (DMAC) Business Profile

Updated before January 2025

Company Overview

DiaMedica Therapeutics, Inc. (NASDAQ: DMAC) is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from serious medical conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, DiaMedica focuses on developing innovative treatments for neurological and kidney diseases. The company is led by a team of experienced executives and researchers, including Rick Pauls, who serves as the President and Chief Executive Officer. Under his leadership, DiaMedica has made significant strides in advancing its pipeline of therapeutic candidates.

Core Business Segments

Neurological Disorders

DiaMedica’s primary focus is on developing treatments for neurological conditions, particularly acute ischemic stroke (AIS). The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 (KLK1), a protein with potential therapeutic benefits for restoring blood flow and reducing inflammation in stroke patients. DM199 is currently undergoing clinical trials and has shown promising results in improving patient outcomes.

Kidney Diseases

In addition to neurological disorders, DiaMedica is also targeting chronic kidney diseases (CKD), including diabetic kidney disease. DM199 is being evaluated for its potential to improve kidney function and reduce disease progression in patients with CKD. This dual focus on neurological and kidney diseases positions DiaMedica as a key player in addressing unmet medical needs in these areas.

Business Model

DiaMedica operates as a research-driven biopharmaceutical company, focusing on the discovery, development, and commercialization of innovative therapies. The company generates revenue primarily through partnerships, licensing agreements, and potential future product sales. By leveraging its proprietary technology platform, DiaMedica aims to develop treatments that address significant gaps in the current standard of care. The company also collaborates with academic institutions and research organizations to advance its scientific understanding and accelerate the development of its pipeline candidates.

Strategic Direction

DiaMedica’s strategic direction is centered on advancing its clinical programs and expanding its therapeutic pipeline. Key priorities include:

  • Advancing DM199 Clinical Trials: The company is focused on completing Phase 2 and Phase 3 clinical trials for DM199 in both acute ischemic stroke and chronic kidney disease.
  • Regulatory Approvals: DiaMedica is working closely with regulatory agencies to secure approvals for its lead product candidate.
  • Pipeline Expansion: The company is exploring additional indications for DM199 and other potential therapeutic candidates.
  • Sustainability Goals: DiaMedica is committed to conducting its operations in an environmentally and socially responsible manner, ensuring long-term sustainability.

Competitive Landscape

DiaMedica operates in a highly competitive biopharmaceutical industry, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Biogen Inc. (neurological disorders)
  • Amgen Inc. (kidney diseases)
  • AstraZeneca (cardiovascular and renal diseases)
  • Novo Nordisk (diabetes-related kidney conditions)

Despite the competition, DiaMedica differentiates itself through its innovative approach to drug development and its focus on addressing unmet medical needs.

Risk Factors

Like any biopharmaceutical company, DiaMedica faces several risks, including:

  • Clinical Trial Risks: The success of the company’s pipeline depends on the outcomes of clinical trials, which are inherently uncertain.
  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s ability to commercialize its products.
  • Market Dependence: DiaMedica’s future revenue is heavily dependent on the success of DM199.
  • Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Financial Risks: As a clinical-stage company, DiaMedica has limited revenue and relies on external funding to support its operations.

Recent Developments

DiaMedica has made significant progress in advancing its clinical programs. Recent developments include:

  • DM199 Clinical Trials: The company has reported positive interim results from its Phase 2 clinical trials for DM199 in acute ischemic stroke and chronic kidney disease.
  • Regulatory Milestones: DiaMedica has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for DM199, highlighting its potential to address unmet medical needs.
  • Partnerships: The company has entered into collaborations with leading research institutions to further explore the therapeutic potential of DM199.
  • Global Developments: The COVID-19 pandemic has posed challenges to clinical trial enrollment and supply chain logistics, but DiaMedica has implemented measures to mitigate these impacts.

Investment Considerations

Strengths

  • Innovative Pipeline: DM199 has the potential to address significant unmet medical needs in stroke and kidney disease.
  • Experienced Leadership: The company is led by a team of seasoned executives with a proven track record in drug development.
  • Regulatory Support: Fast Track designation from the FDA underscores the potential of DM199.
  • Focused Strategy: DiaMedica’s dual focus on neurological and kidney diseases provides diversification and growth opportunities.

Risks

  • Clinical and Regulatory Uncertainty: The success of the company’s pipeline is not guaranteed.
  • Financial Dependence: DiaMedica relies on external funding to support its operations.
  • Market Competition: The biopharmaceutical industry is highly competitive, with numerous players targeting similar indications.

Conclusion

DiaMedica Therapeutics, Inc. is a promising clinical-stage biopharmaceutical company with a focus on developing innovative treatments for neurological and kidney diseases. With its lead product candidate, DM199, showing potential in addressing significant unmet medical needs, DiaMedica is well-positioned for future growth. However, the company faces risks inherent to the biopharmaceutical industry, including clinical and regulatory uncertainties. Investors should carefully consider these factors when evaluating DiaMedica as a potential investment opportunity.